Pharvaris (NASDAQ:PHVS - Get Free Report)'s share price fell 3.5% during mid-day trading on Tuesday . The stock traded as low as $18.36 and last traded at $18.36. 4,298 shares changed hands during trading, a decline of 95% from the average session volume of 87,379 shares. The stock had previously closed at $19.02.
Analyst Upgrades and Downgrades
Separately, Oppenheimer increased their price objective on Pharvaris from $38.00 to $42.00 and gave the stock an "outperform" rating in a report on Friday, September 6th.
Check Out Our Latest Stock Report on Pharvaris
Pharvaris Price Performance
The company has a fifty day simple moving average of $20.88 and a two-hundred day simple moving average of $19.37. The company has a market capitalization of $610.37 million, a P/E ratio of -6.85 and a beta of -3.17.
Institutional Investors Weigh In On Pharvaris
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC acquired a new position in Pharvaris during the third quarter valued at approximately $106,000. Geode Capital Management LLC grew its stake in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock valued at $685,000 after buying an additional 5,753 shares during the last quarter. Public Employees Retirement System of Ohio bought a new position in Pharvaris in the 3rd quarter worth $57,000. Jane Street Group LLC acquired a new position in Pharvaris during the 3rd quarter worth $526,000. Finally, Sphera Funds Management LTD. boosted its holdings in Pharvaris by 8.9% during the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company's stock valued at $8,136,000 after acquiring an additional 36,027 shares during the period.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
